Form S-8 POS Xenon Pharmaceuticals
As filed with the Securities and Exchange Commission on June 3, 2026
Registration Statement No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
POST-EFFECTIVE AMENDMENT NO. 1 TO:
FORM S-8 REGISTRATION STATEMENT NO. 333-199860
FORM S-8 REGISTRATION STATEMENT NO. 333-202765
FORM S-8 REGISTRATION STATEMENT NO. 333-210050
FORM S-8 REGISTRATION STATEMENT NO. 333-216543
FORM S-8 REGISTRATION STATEMENT NO. 333-223497
FORM S-8 REGISTRATION STATEMENT NO. 333-230103
FORM S-8 REGISTRATION STATEMENT NO. 333-237036
FORM S-8 REGISTRATION STATEMENT NO. 333-238895
FORM S-8 REGISTRATION STATEMENT NO. 333-265377
FORM S-8 REGISTRATION STATEMENT NO. 333-279962
REGISTRATION STATEMENT
Under
THE SECURITIES ACT OF 1933
XENON PHARMACEUTICALS INC.
(Exact name of registrant as specified in its charter)
Canada |
98-0661854 |
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) |
3650 Gilmore Way
Burnaby, British Columbia V5G 4W8
Canada
(Address of principal executive offices, including zip code)
2026 Equity Incentive Plan
Amended and Restated 2014 Equity Incentive Plan
(Full title of the plan)
Thomas P. Kelly
Chief Financial Officer
Xenon Pharmaceuticals Inc.
3650 Gilmore Way
Burnaby, British Columbia V5G 4W8
Canada
(Name and address of agent for service)
(604) 484-3300
(Telephone number, including area code, of agent for service)
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer |
|
☒ |
|
Accelerated filer |
|
☐ |
|
|
|
|
|||
Non-accelerated filer |
|
☐ |
|
Smaller reporting company |
|
☐ |
|
|
|
|
|
|
|
Emerging growth company |
|
☐ |
|
|
|
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
EXPLANATORY NOTE
Pursuant to Securities Act Forms Corporation Finance Interpretation 126.43 (“CFI 126.43”) published by the Securities and Exchange Commission (the “Commission”), Xenon Pharmaceuticals Inc. (the “Registrant”) is filing this Post-Effective Amendment No. 1 to Registration Statements on Form S-8 (this “Post-Effective Amendment”) to the following registration statements on Form S-8 (collectively, the “Registration Statements”) filed by the Registrant with the Commission:
On June 2, 2026, the Registrant’s shareholders approved the Registrant’s 2026 Equity Incentive Plan (the “2026 Plan”), which replaces the Amended and Restated 2014 Plan. No further awards will be made under the Amended and Restated 2014 Plan.
-1-
The number of Common Shares initially authorized for issuance pursuant to the awards under the 2026 Plan includes (a) 4,400,000 Common Shares, (b) 2,873,223 Common Shares, which equals the number of shares available for future grant under the Amended and Restated 2014 Plan as of June 2, 2026 and (c) up to 11,788,376 Common Shares, underlying awards outstanding under the Amended and Restated 2014 Plan that, on or after June 2, 2026, terminate, expire or lapse for any reason without the delivery of shares to the holder thereof (such shares under clauses (b) and (c), the “Carryover Shares”).
Contemporaneously with the filing of this Post-Effective Amendment, the Registrant is filing a Registration Statement on Form S-8 to register the 4,400,000 newly authorized Common Shares that have become available for offer or sale pursuant to the 2026 Plan, which number does not include the Carryover Shares.
In accordance with CFI 126.43 and pursuant to the undertaking in Item 512(a)(1)(iii) of Regulation S-K that the Registrant disclose a material change in the plan of distribution as it was originally disclosed in the Registration Statements, this Post-Effective Amendment is filed to indicate that the Registration Statements will also cover the issuance of the Carryover Shares under the 2026 Plan (as such shares would no longer be issuable under the Amended and Restated 2014 Plan as described above). No additional securities are being registered by this Post-Effective Amendment.
PART I
INFORMATION REQUIRED IN THE PROSPECTUS
The information specified in Item 1 and Item 2 of Part I of Form S-8 is omitted from this Post-Effective Amendment in accordance with the provisions of Rule 428 under the Securities Act of 1933, as amended (the "Securities Act"), and the introductory note to Part I of Form S-8. The documents containing the information specified in Part I of Form S-8 will be delivered to the participants in the equity benefit plans covered by this Post-Effective Amendment as specified by Rule 428(b)1) under the Securities Act.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3. Incorporation of Documents by Reference
The following documents previously filed with the Commission are hereby incorporated by reference:
-2-
All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Act, prior to the filing of a post-effective amendment which indicates that all securities registered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents; provided, however, that documents or information deemed to have been furnished and not filed in accordance with the rules of the Commission shall not be deemed incorporated by reference into the Registration Statements. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of the Registration Statements to the extent that a statement contained herein or in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of the Registration Statements.
Under no circumstances will any information furnished under current items 2.02 or 7.01 of Form 8-K be deemed incorporated herein by reference unless such Form 8-K expressly provides to the contrary.
Item 4. Description of Securities
Not applicable.
Item 5. Interests of Named Experts and Counsel
Not applicable.
Item 6. Indemnification of Directors and Officers
Under the Canada Business Corporations Act (the “CBCA”), the Registrant may indemnify its current or former directors or officers or any other individuals who act or have acted at its request as a director or officer, or an individual acting in a similar capacity, of another entity, against all costs, charges, and expenses, including an amount paid to settle an action or satisfy a judgment, reasonably incurred by the individual in respect of any civil, criminal, administrative, investigative or other proceeding in which the individual is involved because of his or her association with the Registrant or the other entity. The CBCA also provides that the Registrant may advance moneys to a director, officer or other individual for costs, charges and expenses reasonably incurred in connection with such a proceeding. The individual shall repay the moneys to the Registrant if indemnification of the individual is ultimately prohibited under the CBCA, as described below.
Indemnification is prohibited under the CBCA unless the individual:
-3-
The Registrant’s by-laws require it to indemnify each of its directors, officers, former directors and officers and persons who act or acted at its request as a director or officer, or in a similar capacity, of a body corporate to the fullest extent permitted under the CBCA. The Registrant will indemnify such individual against all costs, charges and expenses, including an amount paid to settle an action or proceeding to which the individual is made a party by reason of being or having been a director or officer of the Registrant or such body corporate. The Registrant’s by-laws also require it to, with the approval of a court, indemnify such individual referred to above, in respect of an action by or on behalf of it or such body corporate to procure a judgment in its favor, to which the individual is made a party by reason of being or having been a director or an officer of the Registrant or such body corporate, against all costs, charges and expenses reasonably incurred by him in connection with such action. However, the Registrant shall not indemnify such individual if the individual did not act honestly and in good faith with a view to the Registrant’s best interests or, in the case of a criminal or administrative action or proceeding that is enforced by a monetary penalty, the individual did not have reasonable grounds for believing that his or her conduct was lawful.
The Registrant’s by-laws authorize it, with the approval of its board of directors, to purchase and maintain insurance for the benefit of any person its board of directors may from time to time determine.
The Registrant has entered into indemnification agreements with each of its directors and certain officers. As provided by its by-laws, these agreements, among other things, require the Registrant to indemnify each director and officer to the fullest extent permitted by Canadian law, including indemnification of all costs, charges and expenses reasonably incurred by such person in any action or proceeding, including, with the approval of a court, any action or proceeding by or in right of it, arising out of the person’s services as a director or officer; provided that, the Registrant will not indemnify such individual if, among other things, he or she did not act honestly and in good faith with a view to its best interests and, in the case of a criminal or penal action, the individual did not have reasonable grounds for believing that his or her conduct was lawful.
Insofar as indemnification of liabilities arising under the Securities Act may be permitted to members of the Registrant’s board of directors, officers or persons controlling it pursuant to the foregoing provisions, the Registrant has been informed that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.
See also the undertakings set out in response to Item 9 herein.
Item 7. Exemption from Registration Claimed
Not applicable.
Item 8. Exhibits
Exhibit |
|
Description of Document |
|
Incorporated by Reference |
||||||
|
|
Form |
|
File No. |
|
Exhibit |
|
Filing Date |
||
|
|
|
|
|
|
|
|
|
|
|
4.1 |
|
|
S-1/A |
|
333-198666 |
|
4.1 |
|
10/6/2014 |
|
|
|
|
|
|
|
|
|
|
|
|
4.2 |
|
Amended and Restated 2014 Equity Incentive Plan and related form agreement. |
|
8-K |
|
001-36687 |
|
10.1 |
|
6/5/2024 |
|
|
|
|
|
|
|
|
|
|
|
4.3 |
|
|
8-K |
|
001-36687 |
|
10.1 |
|
6/3/2026 |
|
|
|
|
|
|
|
|
|
|
|
|
5.1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5.2 |
|
|
S-8 |
|
333-199860 |
|
5.1 |
|
11/5/2014 |
|
|
|
|
|
|
|
|
|
|
|
|
5.3 |
|
|
S-8 |
|
333-202765 |
|
5.1 |
|
3/16/2015 |
|
|
|
|
|
|
|
|
|
|
|
|
5.4 |
|
|
S-8 |
|
333-210050 |
|
5.1 |
|
3/9/2016 |
|
|
|
|
|
|
|
|
|
|
|
|
5.5 |
|
|
S-8 |
|
333-216543 |
|
5.1 |
|
3/8/2017 |
|
-4-
Item 9. Undertakings
(a) The undersigned Registrant hereby undertakes:
(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:
-5-
(i) To include any prospectus required by Section 10(a)(3) of the Securities Act;
(ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective Registration Statement; and
(iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;
provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) of this section do not apply if the registration statement is on Form S-8, and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in this Registration Statement.
(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
(b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in this registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
(c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.
-6-
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Needham Heights, Massachusetts, on June 3, 2026.
|
|
XENON PHARMACEUTICALS INC. |
|
|
|
|
|
|
|
By: |
/s/ Thomas P. Kelly |
|
|
|
Thomas P. Kelly |
|
|
|
Chief Financial Officer |
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Ian Mortimer and Thomas P. Kelly as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities (including his or her capacity as a director and/or officer of Xenon Pharmaceuticals Inc.) to sign any or all amendments (including post-effective amendments) to this registration statement on Form S-8, as amended, and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agents or any of them, or any substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement on Form S-8 has been signed by the following persons in the capacities and on the dates indicated.
Name |
|
Title |
|
Date |
|
|
|
|
|
/s/ Ian Mortimer |
|
President, Chief Executive Officer and Director (Principal Executive Officer) |
|
June 3, 2026 |
Ian Mortimer |
|
|
|
|
|
|
|
|
|
/s/ Thomas P. Kelly |
|
Chief Financial Officer (Principal Financial and Accounting Officer) |
|
June 3, 2026 |
Thomas P. Kelly |
|
|
|
|
|
|
|
|
|
/s/ Dawn Svoronos |
|
Chair of the Board of Directors |
|
June 3, 2026 |
Dawn Svoronos |
|
|
|
|
|
|
|
|
|
/s/ Gillian Cannon |
|
Director |
|
June 3, 2026 |
Gillian Cannon |
|
|
|
|
|
|
|
|
|
/s/ Steven Gannon |
|
Director |
|
June 3, 2026 |
Steven Gannon |
|
|
|
|
|
|
|
|
|
/s/ Elizabeth Garofalo |
|
Director |
|
June 3, 2026 |
Elizabeth Garofalo |
|
|
|
|
|
|
|
|
|
/s/ Justin Gover |
|
Director |
|
June 3, 2026 |
Justin Gover |
|
|
|
|
|
|
|
|
|
/s/ Patrick Machado |
|
Director |
|
June 3, 2026 |
Patrick Machado |
|
|
|
|
|
|
|
|
|
/s/ Gary Patou |
|
Director |
|
June 3, 2026 |
Gary Patou |
|
|
|
|
ATTACHMENTS / EXHIBITS
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Port Houston Remembers Former Port Commissioner Dean E. Corgey
- Keycafe Expands Executive Leadership with Appointments of Rudi Airisto and Robert Johnston as Company Enters Next Phase of Global Growth
- Indie-Pop Rising Star Addict Announces New Single ‘Call Me Home’ Out July 3, 2026
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share